HYPRHO D

Hyprho D Adverse Events Reported to the FDA Over Time

How are Hyprho D adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Hyprho D, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Hyprho D is flagged as the suspect drug causing the adverse event.

Most Common Hyprho D Adverse Events Reported to the FDA

What are the most common Hyprho D adverse events reported to the FDA?

Drug Exposure During Pregnancy	134 (20.71%)
Adverse Event	91 (14.06%)
Metal Poisoning	87 (13.45%)
Neurotoxicity	73 (11.28%)
Autism	11 (1.7%)
Developmental Delay	10 (1.55%)
Nervous System Disorder	9 (1.39%)
Adenoidal Hypertrophy	8 (1.24%)
Attention Deficit/hyperactivity Dis...	8 (1.24%)
Bronchiolitis	8 (1.24%)
Croup Infectious	8 (1.24%)
	Show More
Interstitial Lung Disease	8 (1.24%)
Laryngeal Stenosis	8 (1.24%)
Otitis Media Chronic	8 (1.24%)
Viral Pharyngitis	8 (1.24%)
Anxiety	7 (1.08%)
Depression	7 (1.08%)
Headache	7 (1.08%)
Insomnia	7 (1.08%)
Meconium In Amniotic Fluid	7 (1.08%)
Stress	7 (1.08%)
Vaginitis Bacterial	7 (1.08%)
Hyperhidrosis	6 (.93%)
Condition Aggravated	5 (.77%)
Diarrhoea	5 (.77%)
Neurodevelopmental Disorder	5 (.77%)
Respiratory Tract Infection	5 (.77%)
Congenital Anomaly	4 (.62%)
Gastrointestinal Disorder	4 (.62%)
Immune System Disorder	4 (.62%)
Learning Disability	4 (.62%)
Abdominal Discomfort	3 (.46%)
Aversion	3 (.46%)
Blood Mercury Abnormal	3 (.46%)
Drug Ineffective	3 (.46%)
Dysphagia	3 (.46%)
Foetal Tobacco Exposure	3 (.46%)
Hearing Impaired	3 (.46%)
Stridor	3 (.46%)
Abnormal Behaviour	2 (.31%)
Adverse Drug Reaction	2 (.31%)
Aggression	2 (.31%)
Congenital Oral Malformation	2 (.31%)
Deafness	2 (.31%)
Encephalopathy	2 (.31%)
Exposure To Toxic Agent	2 (.31%)
Expressive Language Disorder	2 (.31%)
Forceps Delivery	2 (.31%)
Haematuria	2 (.31%)
Head Banging	2 (.31%)
Laboratory Test Abnormal	2 (.31%)
Maternal Drugs Affecting Foetus	2 (.31%)
Motor Dysfunction	2 (.31%)
Oppositional Defiant Disorder	2 (.31%)
Prolonged Labour	2 (.31%)
Screaming	2 (.31%)
Social Problem	2 (.31%)
Speech Disorder Developmental	2 (.31%)
Communication Disorder	1 (.15%)
Disturbance In Social Behaviour	1 (.15%)
Dyspnoea	1 (.15%)
Ear Infection	1 (.15%)
Fine Motor Delay	1 (.15%)
Injury	1 (.15%)
Nausea	1 (.15%)
Neonatal Aspiration	1 (.15%)
Neonatal Disorder	1 (.15%)
Nerve Root Injury	1 (.15%)
Neurological Symptom	1 (.15%)
Psychomotor Skills Impaired	1 (.15%)
Vacuum Extractor Delivery	1 (.15%)
Vomiting	1 (.15%)
Weight Decreased	1 (.15%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Hyprho D, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Hyprho D is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Hyprho D

What are the most common Hyprho D adverse events reported to the FDA?

Chemical Injury And Poisoning	228 (35.24%)
Therapeutic And Nontherapeutic Effe...	96 (14.84%)
Neurological	88 (13.6%)
Viral Infectious	24 (3.71%)
Upper Respiratory Tract Disorders	19 (2.94%)
Anxiety Disorders	14 (2.16%)
Infections - Pathogen Unspecified	14 (2.16%)
Mental Impairment	11 (1.7%)
Cognitive And Attention Disorders	10 (1.55%)
Gastrointestinal Signs	8 (1.24%)
Lower Respiratory Tract Disorders	8 (1.24%)
	Show More
Bacterial Infectious	7 (1.08%)
Depressed Mood Disorders	7 (1.08%)
Headaches	7 (1.08%)
Placental, Amniotic And Cavity Diso...	7 (1.08%)
Sleep Disorders	7 (1.08%)
Lifestyle Issues	6 (.93%)
Personality Disorders	6 (.93%)
Skin Appendage Conditions	6 (.93%)
Communication Disorders	5 (.77%)
Developmental	5 (.77%)
Gastrointestinal Motility And Defec...	5 (.77%)
Hearing	5 (.77%)
Congenital And Hereditary	4 (.62%)
Gastrointestinal Conditions	4 (.62%)
Immune	4 (.62%)
Obstetric And Gynecological Therape...	3 (.46%)
Toxicology And Therapeutic Drug Mon...	3 (.46%)
Changes In Physical Activity	2 (.31%)
Encephalopathies	2 (.31%)
Gastrointestinal Tract Disorders Co...	2 (.31%)
Injuries	2 (.31%)
Investigations, Imaging And Histopa...	2 (.31%)
Maternal Complications Of Labour An...	2 (.31%)
Psychiatric And Behavioural Symptom...	2 (.31%)
Urinary Tract Signs	2 (.31%)
Movement Disorders	1 (.15%)
Neonatal And Perinatal Conditions	1 (.15%)
Neonatal Respiratory	1 (.15%)
Physical Examination Topics	1 (.15%)
Respiratory	1 (.15%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Hyprho D, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Hyprho D is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.